WA-AUTH0
15.6.2021 15:03:38 CEST | Business Wire | Press release
Auth0 , the modern identity platform, today announced the launch of Auth0 WebAuthn Passwordless , an authentication feature that enables end-users to seamlessly log in with a biometric identifier — such as facial recognition or a fingerprint — as a convenient and secure alternative to a traditional password. Removing the need for long, complex passwords, Auth0 WebAuthn Passwordless provides a frictionless experience for end-users, while reducing the significant password management burden for companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005339/en/
Today’s abundance of applications and systems has never had more access points, leaving organizations and their end-users vulnerable to attacks. A reliance on passwords as a primary means of authentication, combined with users’ tendency to reuse passwords across applications, presents a number of security, user experience, and cost issues. According to a 2021 Data Breach Investigations Report by Verizon , compromised passwords are responsible for 84% of breaches. Passwordless authentication mitigates these challenges, and offers increased security and trust for applications, devices, and services providers; faster and smoother login experiences for their end-users; and cost savings by eliminating the need for password management support.
“Despite ongoing guidance around proper password creation and repeated warnings against password reuse, consumers crave convenience and continue to use the easiest and most convenient path for application access,” said Shiv Ramji, Chief Product Officer at Auth0. “A passwordless future is largely being driven by two primary forces — security and convenience. Companies want to secure the vulnerabilities that come with passwords, and they also want to offer their users a better digital experience. Auth0 WebAuthn Passwordless is a modern option for organizations looking to attract and retain users.”
With Auth0 WebAuthn Passwordless, users can authenticate with Web Authentication-powered (WebAuthn) biometrics, the official web standard for passwordless authentication as published by W3C and used by FIDO , for first-factor authentication. This form of authentication eliminates security weaknesses based on password reuse, since passwords are not required. Additionally, Auth0 WebAuthn Passwordless is an ideal option for companies looking to build and provide an authentication experience supporting conversion and retention of users who want more choice and less friction in their login experience.
Auth0 WebAuthn Passwordless eliminates the need for users to enter username and password credentials and enables simpler login with a biometric identifier such as facial recognition like Apple Face ID, or a fingerprint scan on a mobile device or laptop. The biometric data remains stored on the device, alleviating privacy and security concerns for end-users. The feature also allows end-users to progressively enroll devices one at a time, as they use them, without needing a centralized portal, giving them the flexibility of having multiple passwordless authentication options — an advanced, unique capability that maximizes end-user adoption and enables a faster transition from passwords to passwordless, benefiting both end-users and organizations.
More detailed information on Auth0 WebAuthn Passwordless can be found here: 7 Things You Need to Know About Passwordless Authentication (whitepaper) and on Auth0’s blog .
Auth0, recently acquired by Okta , provides a modern identity platform that helps organizations meet the security, privacy, and convenience needs of their users. Please visit Auth0 identity OS to learn more.
About Auth0
Auth0’s modern approach to identity enables organizations to provide secure access to any application, for any user. The Auth0 platform is a highly customizable identity operating system that is as simple as development teams want and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005339/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom